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Horse or Zebra?
The Common and Uncommon Presentations of CVID
Jessica Telleria (Medical Student); Vishaal Sridhar (Medical Student); Joy Smith, MD

Introduction
•Common Variable Immunodeficiency
(CVID) is the most frequently encountered
primary immunodeficiency. It consists of a
group of heterogenous antibody deficiencies
which most commonly predisposes patients
to recurrent respiratory infections. However,
some patients do present with other
features of a weakened immune system
such as autoimmune. diseases and/or
malignancies.[1]
•Disease of B cell differentiation failure.

Timeline
Day 1
12/6

• Initial workup and treatment for CAP
Day 2
12/7

Day 3
12/8

Patient Information
1. 47 year old Hispanic male presents to
the ED with three-day history of
dyspnea, fever, chills and cough
productive of clear sputum.
2. No significant past medical history until
the preceding year, when he was
hospitalized 3-4 times with a diagnosis
of pneumonia.
3. He works as a truck driver traveling in
the southwest United States, but
primarily in Arizona.
4. The patient reported temporary
resolution of symptoms with each
antibiotic treatment (name unknown).
5. He also reports persistent conjunctivitis
for the past year.
6. He denies any significant childhood
illness or hospitalization.
7. He admits to two casual sexual contacts
in the last year.

Admission
•Temp 98.5
•BP 74/46
•HR 118
•Dyspnea with extended conversation;
diffuse coarse rhonchi with diminished air
exchange in bilateral bases
•Conjunctivae mildly injected with purulent
matted discharge in the upper eyelashes
•WBC 35,500 with predominance of
neutrophils

• Initial Presentation
• EKG shows ST elevation

Day 6
12/11

Day 14
12/19

• ECHO shows pericardial tamponade
• pericardial window
• Hypogammaglobulinemia
• Pseudomonas on pericardial effusion culture
• bone marrow bx and secondary workup (bx
results negative for malignancy)

• Discharged on maxipime, IVIG q month

Diagnostic Assessment
•Serology: complement levels,
Immunoglobulins, rheumatoid screen,
Coccidiomycosis antibody, Histoplasma
antibody, HIV screen negative, quantiferon
negative
•Bone marrow biopsy negative
•EKG: diffuse ST elevations
•ECHO: pericardial tamponade
•Pericardial fluid culture: Pseudomonas
•Sputum culture: respiratory flora
•Urine culture: negative
•Conjunctival fluid culture: normal flora
•CXR: opacities at lung bases
•Chest CT: bibasilar pneumonias,
extensive mediastinal adenopathy,
pericardial effusion
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Therapeutic Interventions
•Pericardial window performed to alleviate
pericardial tamponade.
•IVIG infusions initiated during hospitalization.
•Azactam given, then changed to Zosyn for
Pseudomonas coverage.
•Maxipime on discharge, with plan for monthly
IVIG infusions.

Follow Up Outcomes
•Summarize clinical course of all
follow up visits including
-Clinician and patient assessed
outcomes
-Intervention adherance and
tolerability
-Adverse and unanticipated
events

Discussion
•This case demonstrates the wide range of presentations with CVID. Quick diagnosis is
imperative to avoid delays in treatment.
Incidence
•1:10,000 - 1:50,000 [2]
•Equally affects both genders
•34% of patients were diagnosed before the age of 10
•Typical delay in diagnosis of 4-9 years [3]
Common Presentations
•CVID is the most common primary immunodeficiency.
•It most commonly presents during puberty and young adulthood.
•Although the presenting symptoms vary widely, it most commonly manifests itself as
recurrent, bacterial, upper or lower respiratory tract infections.
•Other presentations include conjunctivitis, GI infections, chronic lung disease,
autoimmune disease, GI inflammatory disease, and malignancies
•By definition, CVID causes low to absent levels of immunoglobulins, specifically IgG,
IgA and/or IgM, in the absence of any other immunodeficiency state. As such, it is
associated with poor response to immunizations. [4]
Treatments
•CVID is primarily treated with IVIG which has been shown to decrease pulmonary
infections and hospitalizations. [5]
•IVIG is given at a dose of 300 to 400mg/kg every 3-4 weeks. Trough IgG levels are
measured every 6 months after the first dose. [5,6]
•Higher doses can be given if patients have continued major infections or chronic lung
disease. [6]
•Patients on IVIG tend to remain susceptible to sinusitis and gastrointestinal infections.
[7]
•Infections should be treated with antibiotics. Other associated conditions (e.g.
autoimmune disorders, enteropathies, granulomatous disorders) can be treated
symptomatically.
•Patients should receive age appropriate cancer screenings and must be monitored for
malignancies including lymphoma and gastric cancer. [8,9,10]
•Radiation exposure should be limited due to the elevated risk of developing
malignancy
•With the use of IVIG, the major causes of death are complications of chronic lung
disease and malignancies, which can shorten the life span significantly (mean age: mid50’s). [11,12]

